Clinical Trials · global
Remission Signals in Refractory Ulcerative Colitis: PSGL-1 Antibody Moves Toward Controlled Trial
In a small Phase 2 trial, AltruBio’s ALTB-268 led to clinical remission in some patients with an inadequate response to prior advanced therapies. However, the two groups were enrolled sequentially, with no placebo control, leaving efficacy and durability to be verified in the next stage.
For patients with ulcerative colitis whose disease remains uncontrolled despite advanced therapies, a new mechanism of action offers another potential treatment path. On October 20, AltruBio announced that its PSGL-1 antibody ALTB-268 showed signals of clinical remission in an early Phase 2 trial. However, the study cannot yet determine how much of the improvement came from the drug itself.
The open-label trial, called ASCEND UC2a, enrolled patients with moderately to severely active ulcerative colitis who had all responded inadequately to at least one advanced therapy, including biologics, JAK inhibitors, or S1P receptor modulators. At Week 12, 4 of 35 patients in the lower-dose group achieved clinical remission, or 11.4%; 3 of 13 patients in the higher-dose group achieved remission, or 23.1%.
Other measures also provided preliminary clues. Endoscopic improvement was observed in 6 patients in the lower-dose group and 3 in the higher-dose group, while clinical response was observed in 12 and 7 patients, respectively. However, the two groups were enrolled sequentially rather than randomized concurrently. With only 13 patients in the higher-dose group in particular, outcomes in just a few patients could substantially affect the percentages. These findings therefore cannot establish that increasing the dose improves efficacy, nor can they be directly compared with existing drugs.
ALTB-268 is a subcutaneously administered tetravalent agonist antibody targeting PSGL-1, also known as CD162. According to the mechanism proposed by the company, it is designed to reduce the activity of chronically activated effector T cells, driving these cells into exhaustion or apoptosis to modulate the immune response. This is the biological rationale behind the drug’s design; this small trial is not sufficient to demonstrate superior efficacy or safety.
On safety, the company’s announcement stated that injection-site reactions were the most common treatment-emergent adverse events. One serious adverse event occurred in the lower-dose group, and no deaths were reported. The announcement did not specify the nature of the serious event or its relationship to the drug. The limited sample and 12-week induction treatment data are also insufficient to rule out rare risks or risks associated with long-term use.
The results were presented at UEG Week 2026. In a pre-meeting announcement, Wellness Clinical Research, which participated in the study, confirmed that its Puerto Rico investigator Gustavo Albizu-Angulo was listed as a co-author and stated that David T. Rubin of the University of Chicago would present the findings. That announcement did not provide remission figures. The figures reported here come primarily from materials released by AltruBio. BioSpace also carried the same company press release, which cannot be considered independent verification.
The next key step is to evaluate these early signals in a controlled study. AltruBio plans to initiate the global late Phase 2 ASCEND UC2b trial in 2027, evaluating two active drug doses against placebo and enrolling patients both with and without prior advanced therapy. Beyond whether the drug can induce remission, how long responses persist during maintenance treatment will determine the clinical value of this approach to immune modulation.